Antibody-drug gold nanoantennas with Raman spectroscopic fingerprints for in vivo tumour theranostics - Global Medical Discovery

Press/Media: Research


Inspired by the ability of SERS nanoantennas to provide an integrated platform to enhance disease targeting in vivo, we developed a highly sensitive probe for in vivo tumour recognition with the capacity to target specific cancer biomarkers such as epidermal growth factor receptors (EGFR) on human cancer cells and xenograft tumour models. Here, we used ~90nm gold nanoparticles capped by a Raman reporter, encapsulated and entrapped by larger polymers and a FDA antibody-drug conjugate – Cetuximab (Erbitux®) – that specifically targets EGFR and turns off a main signalling cascade for cancer cells to proliferate and survive. These drug/SERS gold nanoantennas present a high Raman signal both in cancer cells and in mice bearing xenograft tumours. Moreover, the  Raman detection signal is accomplished simultaneously by extensive tumour growth inhibition in mice, making these gold  nanoantennas  ideal for cancer nanotheranostics, i.e. tumour detection and tumour cell inhibition at the same time.

Period19 Sept 2014